(1551550) PI3K inhibitor-resistant B-cell lymphomas show distinct functional phenotypes characterized by sensitivity to Bcl-2- or proteasome-inhibition

Primary Author; Presenting Author(s)

• 

  Johanne Uthus Hermansen, MSc

  PhD Student
  Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital
  Oslo, Norway

  Slides

Co-Author(s)

• PA

  Paschalis Athanasiadis, MSc

  Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital
  Oslo, Norway
• YY

  Yanping Yin, PhD

  Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital
  Oslo, Norway
• AA

  Alberto J. Arribas, PhD

  Institute of Oncology Research, Faculty of Biomedical Sciences, USI
  Bellinzona, Switzerland
• LN

  Lene Skou Nilsen, MD

  University Hospital of North Norway
  Tromsø, Norway
• AM

  Anthony R. Mato, MD

  Memorial Sloan Kettering Cancer Center, United States
• FB

  Fransesco Bertoni, MS, PhD

  Institute of Oncology Research, Faculty of Biomedical Sciences, USI
  Bellinzona, Switzerland
• GT

  Geir E. Tjønnfjord, MD, PhD

  Department of Haematology, Oslo University Hospital
  Oslo, Norway
• TA

  Tero Aittokallio, PhD

  Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital
  Oslo, Norway
• SS

  Sigrid S. Skånland, PhD

  Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital
  Oslo, Norway